Rapamune and Focal glomerulosclerosis - a phase IV clinical study of FDA data

Summary:

Focal glomerulosclerosis is reported as a side effect among people who take Rapamune (sirolimus), especially for people who are male, 30-39 old, have been taking the drug for 1 - 2 years also take Mycophenolate Mofetil, and have Constipation.

The phase IV clinical study analyzes which people have Focal glomerulosclerosis when taking Rapamune. It is created by eHealthMe based on reports of 13,732 people who have side effects when taking Rapamune from the FDA, and is updated regularly.

What is Rapamune?

Rapamune has active ingredients of sirolimus. It is often used in kidney transplant. eHealthMe is studying from 13,848 Rapamune users. Check the latest studies of Rapamune.

What is Focal glomerulosclerosis?

Focal glomerulosclerosis (disease that attacks the kidney's filtering system (glomeruli) causing serious scarring) is found to be associated with 15 drugs and 75 conditions by eHealthMe. Check the latest studies of Focal glomerulosclerosis.

On Jul, 15, 2026

13,732 people reported to have side effects when taking Rapamune.
Among them, 11 people (0.08%) have Focal glomerulosclerosis.

Could Rapamune cause Focal glomerulosclerosis?

Among these 11 people:

How long have people been on Rapamune when they have Focal glomerulosclerosis? *

What is the gender of people who have Focal glomerulosclerosis when taking Rapamune? *

female: 50 %
male: 50 %

What is the age of people who have Focal glomerulosclerosis when taking Rapamune? *

What are other drugs people take besides Rapamune? *

What are other side effects people have besides Focal glomerulosclerosis? *

Pneumonia: 3 people, 27.27%
Nephrotic Syndrome (kidney disease with proteinuria, hypoalbuminemia, and oedema): 3 people, 27.27%
Drug Level Increased: 3 people, 27.27%
Disease Recurrence: 2 people, 18.18%
Complications Of Transplanted Kidney: 2 people, 18.18%
Chronic Allograft Nephropathy (failure of kidney transplant): 2 people, 18.18%
Acute Kidney Failure: 2 people, 18.18%
Nephropathy Toxic (damage to kidney due to toxins): 1 person, 9.09%
Kidney Transplant Rejection: 1 person, 9.09%
Interstitial Nephritis (inflammation of the kidney): 1 person, 9.09%

What are the existing conditions these people have? *

Urinary Tract Infection: 3 people, 27.27%
Productive Cough: 3 people, 27.27%
Pain: 3 people, 27.27%
Lower Respiratory Tract Infection: 3 people, 27.27%
Immunodeficiency Disorders: 3 people, 27.27%
Constipation: 3 people, 27.27%
Kidney Transplant Rejection: 2 people, 18.18%

* Approximation only. Some reports may have incomplete information.

Do you take Rapamune and have Focal glomerulosclerosis?

- Check whether Focal glomerulosclerosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rapamune:

Rapamune (13,848 reports)

Browse all side effects of Rapamune:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Focal glomerulosclerosis:

Focal glomerulosclerosis (15 drugs)

Browse all the conditions that are associated with Focal glomerulosclerosis:

Focal glomerulosclerosis (75 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sirolimus (the active ingredients of Rapamune) and Rapamune (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.